SFM
JNCE

Systematic Financial Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Systematic Financial Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-36,265
Closed -$250K – 479
2020
Q2 		$250K Sell
36,265
-19,990
-36% -$108K 0.01% 424
2020
Q1 		$267K Sell
56,255
-9,800
-15% -$56.4K 0.02% 341
2019
Q4 		$577K Buy
+66,055
New +$357K 0.02% 382

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Systematic Financial Management's JNCE Position: Q3 2020 in Review

Systematic Financial Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2020, closing a stake of 36,265 shares — an estimated $250K sold.

Systematic Financial Management first reported a position in JNCE in Q4 2019 and held it in 3 quarters. The position peaked at $577K in Q4 2019. 102 funds tracked by Wall St. Rank hold JNCE as of Q3 2020.

  • Systematic Financial Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Systematic Financial Management sold 36,265 Jounce Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $250K.
  • Systematic Financial Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2019 and held it in 3 quarters.
  • Systematic Financial Management's Jounce Therapeutics, Inc. Common Stock position peaked at $577K in Q4 2019.
  • 102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Systematic Financial Management's 13F filing for Q3 2020, filed 12 Nov 2020.